<DOC>
	<DOCNO>NCT00668512</DOCNO>
	<brief_summary>This Phase I pilot study evaluate toxicity two intra-tumoral injection GSL alpha-GAL patient advance metastatic cutaneous melanoma . Patients fail standard therapy eligible standard treatment eligible study .</brief_summary>
	<brief_title>Intratumoral Injection Of Alpha-Gal Glycosphingolipids</brief_title>
	<detailed_description>A standard Phase I dose escalation model use define maximum tolerate dose ( MTD ) GSL alpha-GAL administer directly tumor lesion two separate injection separate 4-weeks . This trial serve basis future Phase II trial utilize multiple injection GSL alpha-GAL refractory solid tumor . Additionally , study look histologic evidence immune response inject melanoma lesion match see mice . Our hypothesis study second injection GSL alpha-GAL melanoma lesion precipitate allergic autoimmune reaction , cause histologically evident immune response tumor .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Patients recurrent melanoma fail standard therapy , candidate standard therapy . 2 . Patients must least one measurable cutaneous lesion accessible suitable injection GSL alphaGAL . 3 . Patients undergo active treatment chemotherapy , radiotherapy , steroid ( either patient treat physician decide employ therapy time , already try fail ) . If treated modality , treatment complete least two week prior date injection GSL alphaGAL . 4 . Patients judge investigator able undergo safely procedure need inject tumor GSL alphaGAL . 5 . Age &gt; 18 year old . 6 . ECOG ( Eastern Cooperative Oncology Group ) performance &lt; 2 . International Normalized Ratio ( INR ) &lt; 1.5 PTT ( partial thromboplastin time ) great normal limit within 1 week prior intratumoral injection ( For patient may blood thinner ) 7 . Laboratory Criteria ( complete &lt; 2 week enrollment ) Hematologic : ( White Blood Cell Count ) WBC &gt; 3500/mm3 ( absolute neutrophil count ) ANC &gt; 1500/mm3 platelet count &gt; 100 000/ mm3 Hepatic : Total bilirubin &lt; 4.0 mg/dl Renal : Creatinine &lt; 2.2 mg/dl . 8 . Patients must negative HIV ( circulate antibody ) , Hepatitis B ( circulatory antigen ) , Hepatitis C ( circulate antibody ) . 9 . Patients expect survival &gt; 6 week systemic antitumor treatment plan time frame . Patients meet follow exclusion criterion eligible : 1 . Patients pregnant nursing ( PRN serum pregnancy test do week 1 ) . 2 . Patients age 18 . 3 . Patients severe infection septicemia . 4 . Patients history autoimmune disease . 5 . Patients , , active treatment chemotherapy steroid . 6 . Patients refuse HIV/hepatitis test patient sign approve consent form 7 . Patient receive investigational drug within 14 day enrollment expect participate experiment drug study study treatment . 8 . Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>metastatic cutaneous melanoma</keyword>
	<keyword>alpha-gal glycolipids</keyword>
</DOC>